Shield Thera Share News (STX)

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

capAI PLC - focused on artificial intelligence systems for media and medicine - Swings to pretax loss of GBP790,529 in the financial year ended September from profit of GBP21,332 the year prior. No revenue reported, unchanged on-year, while administrative expenses balloon to GBP791,432 from GBP226,866. Last year's figure benefited from write-back of loans and debts of GBP248,198. CapAI believes that AI represents a significant long-term growth theme across multiple sectors. As at September 30, cash and equivalents total GBP96,444 up year-on-year from GBP28,329. "The group remains at an early stage of execution; however, the foundations established during the year under review provide a strong platform for future progress," it says.

----------

Peel Hunt Ltd - London-based investment bank and stockbroker - Says it continues to trade well and ahead of expectations in the second half, supported by strong performance across its Investment Banking and Execution Services franchises. The broker reports healthy M&A and equity capital markets activity among its corporate clients and now expects full-year revenue and profit to come in ahead of current market expectations.

----------

Transense Technologies PLC - Bicester, England-based sensor technology developer - Says full-year profitability is now expected to be materially below the current market view, citing slower-than-expected growth across parts of the business and delays in converting new customer pipelines. The company now expects full-year revenue of no less than GBP5.2 million. Transense says royalty income from Bridgestone’s iTrack system is expected to be around 10% lower than previously anticipated, reflecting softer volumes. It also reports that growth at both SAWsense and Translogik is below market expectations, while customer onboarding has taken longer than planned, pushing revenue recognition into later periods.

----------

RUA Life Sciences PLC - holding company of multiple medical device businesses - Releases results for the 18 months ending September 2025 with comparative figures representing a 12 month period to end March 2024. Pretax loss narrows to GBP200,000 from GBP2.0 million while revenue balloons to GBP6.7 million from GBP6.7 million. "The two year objectives set at the time of the 2023 Strategy Review, of doubling revenues, reducing cash burn and focussing on profitability have been achieved ahead of time through strong trading and the purchase of the Abiss subsidiary in France. We look forward to building upon this success through broadening both services for current customers and expanding the customer base further," comments Chair Geoff Berg.

----------

LPA Group PLC - Essex, England-based engineering company focused on electronic systems - Pretax loss widens to GBP602,000 in the financial year ending September from GBP593,000 the year prior as revenue drops to GBP21.5 million from GBP23.5 million. Order book stands at GBP32.5 million, up from GBP25.3 million, gearing rises to 21.5% from 13.1%. "We have focused on operational resilience, reducing the back orders and getting product out to our customers, on time and in full. We traditionally have a stronger second half of the year but for the first time in 4 years we can see our business plan bearing fruit as we have started 2026 on budget and profitable," company says. Aerospace and Defence was below expectations, LPA says, while Rail aftercare projects in the UK slowed awaiting new funding decisions and subsequent investment, especially with uncertainty around Great British Railways. Industrial and Infrastructure market progression was mostly achieved through "our niche range of specialist electrical 'Niphan' connectors".

----------

Vast Resources PLC - copper and polymetallic miner in Romania, Tajikistan, and Zimbabwe - Pretax loss from continuing operations widens to USD4.4 million in the six months to October from USD3.3 million the year prior. No revenue is disclosed, down from USD211,000. Overhead expenses rise to USD2.9 million from USD1.7 million but cost of sales falls to USD661,000 from USD1.2 million. Higher loss reflects transaction costs associated with the proposed acquisition of Gulf International Minerals Ltd, company explains. These include legal and financial due diligence and advisory costs.

----------

Winking Studios Ltd - Singapore-based video game services firm - Expects to report a 40% jump in revenue in 2025 compared to the prior year's UD31.9 million, marginally higher than current market expectations of USD43.6 million. Shanghai Mineloader Digital Technology Co Ltd, acquired last April, is a "significant driver" of the improved revenue performance, alongside mid-to-high single-digit organic growth from other studios. Adjusted earnings before interest, tax, depreciation and amortisation is expected to be higher by a range of between 7% to 13% than 2024's USD4.8 million. At December 31, indicative artist bookings total at least USD48.6 million over the next 24 months. Of this, around USD34.6 million is expected to be recognised in 2026 as revenue.

----------

Shield Therapeutics PLC - Newcastle, England-based commercial-stage pharmaceutical company - Announces that its partner in China, Beijing Aosaikang Pharmaceutical Co Ltd (ASK), expects to submit the file for marketing authorisation to the China National Medical Products Administration for the approval for AccruFeR in China in the first quarter of 2026. Shield and ASK agree to update various terms of the China license agreement including a development milestone of USD7.9 million payable to Shield by January 31 2026. Shield will use the ASK development milestone to settle its obligations under the milestone monetisation agreement with AOP Health International Management AG and terminate the agreement. The updated deal between Shield and ASK includes a milestone payment of up to USD3 million linked to the final price for AccruFeR in China, and revised royalties of up to 10% based on annual net sales of AccruFeR. AccruFeR is a prescription oral iron therapy designed for adults and children with iron deficiency or iron deficiency anemia.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.